Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2490-2496
Published online before print April 30, 2007, doi: 10.1161/CIRCULATIONAHA.106.667584
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
115/19/2490    most recent
CIRCULATIONAHA.106.667584v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faraday, N.
Right arrow Articles by Becker, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faraday, N.
Right arrow Articles by Becker, D. M.
Related Collections
Right arrow Antiplatelets
Right arrow Aggregation
Right arrow Genetics of cardiovascular disease
Right arrow Platelet function inhibitors
Right arrow Platelets

(Circulation. 2007;115:2490-2496.)
© 2007 American Heart Association, Inc.


Genetics

Heritability of Platelet Responsiveness to Aspirin in Activation Pathways Directly and Indirectly Related to Cyclooxygenase-1

Nauder Faraday, MD; Lisa R. Yanek, MPH; Rasika Mathias, PhD; J. Enrique Herrera-Galeano, MS; Dhananjay Vaidya, MBBS, PhD, MPH; Taryn F. Moy, MS; M. Daniele Fallin, PhD; Alexander F. Wilson, PhD; Paul F. Bray, MD; Lewis C. Becker, MD; Diane M. Becker, ScD

From the Department of Anesthesiology/Critical Care Medicine, Division of Cardiac Surgical Intensive Care (N.F.), Department of Medicine, Division of General Internal Medicine (L.R.Y., J.E.H.-G., D.V., T.F.M., D.M.B.), and Department of Medicine, Division of Cardiology (L.C.B.), Johns Hopkins Medical Institutions, Baltimore, Md; Inherited Disease Research Branch, National Human Genome Research Institute/National Institutes of Health, Baltimore, Md (R.M., A.F.W.); Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md (M.D.F.); and Department of Medicine, Division of Hematology, Jefferson Medical College, Philadelphia, Pa (P.F.B.).

Correspondence to Nauder Faraday, MD, 298 Meyer Bldg, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287. E-mail nfaraday{at}jhmi.edu

Received September 30, 2006; accepted February 23, 2007.

Background— The inability of aspirin (acetylsalicylic acid [ASA]) to adequately suppress platelet function is associated with future risk of myocardial infarction, stroke, and cardiovascular death. Genetic variation is a proposed but unproved mechanism for insufficient ASA responsiveness.

Methods and Results— We examined platelet ASA responsiveness in 1880 asymptomatic subjects (mean age, 44±13 years; 58% women) recruited from 309 white and 208 black families with premature coronary heart disease. Ex vivo platelet function was determined before and after ingestion of ASA (81 mg/d for 2 weeks) with the use of a panel of measures that assessed platelet activation in pathways directly and indirectly related to cyclooxygenase-1, the enzyme inhibited by ASA. The proportion of phenotypic variance related to CHD risk factor covariates was determined by multivariable regression. Heritability of phenotypes was determined with the use of variance components models unadjusted and adjusted for covariates. ASA inhibited arachidonic acid–induced aggregation and thromboxane B2 production by ≥99% (P<0.0001). Inhibition of urinary thromboxane excretion and platelet activation in pathways indirectly related to cyclooxygenase-1 was less pronounced and more variable (inhibition of 0% to 100%). Measured covariates contributed modestly to variability in ASA response phenotypes (r2=0.001 to 0.133). Phenotypes indirectly related to cyclooxygenase-1 were strongly and consistently heritable across races (h2=0.266 to 0.762; P<0.01), but direct cyclooxygenase-1 phenotypes were not.

Conclusions— Heritable factors contribute prominently to variability in residual platelet function after ASA exposure. These data suggest a genetic basis for the adequacy of platelet suppression by ASA and potentially for differences in the clinical efficacy of ASA.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. E. Herrera-Galeano, D. M. Becker, A. F. Wilson, L. R. Yanek, P. Bray, D. Vaidya, N. Faraday, and L. C. Becker
A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated With Increased Platelet Aggregability
Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1484 - 1490.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg., August 1, 2008; 107(2): 552 - 569.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Y. Gasparyan, T. Watson, and G. Y.H. Lip
The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance
J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. E. Freedman
Heritability, Platelet Function, and Aspirin: A Link Established but Cause Unknown
Circulation, May 15, 2007; 115(19): 2468 - 2470.
[Full Text] [PDF]


Home page
ASH Education BookHome page
D. J. Fitzgerald and A. Maree
Aspirin and Clopidogrel Resistance
Hematology, January 1, 2007; 2007(1): 114 - 120.
[Abstract] [Full Text] [PDF]